调节性T细胞在前列腺癌患者外周血中表达的研究

李宁; 董彤; 王于勇; 胡逸轩; 李昶灸; 谢玺; 何华东

doi:10.13201/j.issn.1001-1420.2021.06.010

调节性T细胞在前列腺癌患者外周血中表达的研究

- 1. 浙江大学医学院附属杭州市第一人民医院泌尿外科(杭州, 310006);
- 2. 南京医科大学附属杭州医院
基金项目:
浙江省医药卫生科技青年人才计划项目(No:2019RC241)

详细信息

通讯作者: 何华东,E-mail:plumber19@163.com

中图分类号: R737.25

收稿日期: 2020-06-14

Expression of regulatory T cells in peripheral blood of prostate cancer patients

- 1. Department of Urology, Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, China;
- 2. Affiliated Hangzhou Hospital, Nanjing Medical University

More Information

Corresponding author: HE Huadong, E-mail: plumber19@163.com

Received Date: 14 June 2020

摘要

摘要: 目的:探讨不同分期前列腺癌患者外周血中CD4⁺CD25⁺CD127^low/-调节性T细胞(Tregs)比例变化及临床意义。方法:将2018年5月—2019年11月期间杭州市第一人民医院泌尿外科收治的部分前列腺癌患者(共90例)进行分组并招募志愿者,采集外周血处理后行流式细胞术,分析前列腺癌患者与正常对照组,以及不同分级前列腺癌组CD4⁺CD25⁺CD127^low/-表达水平是否存在差异性。结果:前列腺癌患者组外周血中的CD4⁺CD25⁺CD127^low/-Tregs表达水平与对照组比较差异有统计学意义(P<0.01);随着危险分级升高CD4⁺CD25⁺CD127^low/-Tregs的表达水平有升高趋势,且不同分级间表达水平差异有统计学意义(高危组vs.中危组,P<0.05;高危组vs.低危组,P<0.001;中危组vs低危组,P<0.001)。结论:外周血中CD4⁺CD25⁺CD127^low/-Tregs在前列腺癌患者中显著增加,且与前列腺癌的发生发展密切相关,其可为前列腺癌患者早期诊断和免疫治疗提供理论基础。
- 前列腺癌 /
- 外周血 /
- 免疫治疗
Abstract: Objective: To explore the changes and clinical significance of CD4⁺CD25⁺CD127^low/- regulatory T cells(Tregs) in peripheral blood of patients with prostate cancer(PCa) at different stages.Methods: We selected some patients with PCa admitted from May 2018 to Nov. 2019 and recruited volunteers, and collected their peripheral blood for flow cytometry. The expression of CD4⁺CD25⁺CD127^low/- Tregs in PCa patients of different grades and volunteers groups were analysed.Results: The expression of CD4⁺CD25⁺CD127^low/-Tregs in the peripheral blood of patients with PCa was significantly different from that of the volunteers group(P<0.01). With the increase of grade, the expression of CD4⁺CD25⁺CD127^low/- Tregs increased, and the difference in expression levels among different grades was statistically significant.Conclusion: CD4⁺CD25⁺CD127^low/- Tregs in peripheral blood significantly increases in patients with PCa, and is closely related to the occurrence and development of PCa, which can provide a theoretical basis for early diagnosis and immunotherapy of patients with PCa.
- prostate cancer /
- peripheral blood /
- immunotherapy

HTML全文

参考文献(18)

[1]	Wild CP,Weiderpass E,Stewart BW.World Cancer Report Cancer research for cancer prevention[M].LYON:World Health Organization International Agency for Research on Cancer,2020.
[2]	郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,;41(1):19-28.
[3]	Cornford P,van den Bergh RCN,Briers E,et al.EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer.Part II-2020 Update:Treatment of Relapsing and Metastatic Prostate Cancer[J].Eur Urol,2021,79(2):263-282.
[4]	中国抗癌协会泌尿男生殖系肿瘤专业委员会.2018版转移性前列腺癌诊治中国专家共识[J].中华外科杂志,2018,56(9):646-652.
[5]	麦海星,陈立军.免疫检查点抑制剂在膀胱尿路上皮癌中的研究进展[J].临床泌尿外科杂志,2019,34(4):322-326.
[6]	Strasner A,Karin M.Immune Infiltration and Prostate Cancer[J].Front Oncol,2015,5:128.
[7]	Cai J,Wang D,Zhang G,et al.The Role Of PD-1/PD-L1 Axis In Treg Development And Function:Implications For Cancer Immunotherapy[J].Onco Targets Ther,2019,12:8437-8445.
[8]	Brusa D,Simone M,Gontero P,et al.Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy:profile comparison[J].Int J Urol,2013,20(10):971-978.
[9]	Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995,155(3):1151-1164.
[10]	Barbi J,Pardoll D,Pan F.Treg functional stability and its responsiveness to the microenvironment[J].Immunol Rev,2014,259(1):115-139.
[11]	杨晓宇,苏秀兰.炎症与肿瘤微环境在肿瘤发生中的作用[J].医学研究杂志,2018,47(6):6-10.
[12]	祝丽晶,侯盼飞,潘艳,等.调节性T细胞与肿瘤放疗[J].现代肿瘤医学,2019,27(22):4128-4130.
[13]	Wang H,Franco F,Ho PC.Metabolic Regulation of Tregs in Cancer:Opportunities for Immunotherapy[J].Trends Cancer,2017,3(8):583-592.
[14]	Davidsson S,Andren O,Ohlson AL,et al.FOXP3+ regulatory T cells in normal prostate tissue,postatrophic hyperplasia,prostatic intraepithelial neoplasia,and tumor histological lesions in men with and without prostate cancer[J].Prostate,2018,78(1):40-47.
[15]	Walker LS.Treg and CTLA-4:two intertwining pathways to immune tolerance[J].J Autoimmun,2013,45:49-57.
[16]	刘家玲,王仕敏,卓召振,等.肿瘤微环境中靶向调节性T细胞免疫治疗策略[J].中国医药导报,2018,15(10):46-50.
[17]	Kwon ED,Drake CG,Scher HI,et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712.
[18]	Alaia C,Boccellino M,Zappavigna S,et al.Ipilimumab for the treatment of metastatic prostate cancer[J].Expert Opin Biol Ther,2018,18(2):205-213.